Table 1 Study population and comparison to full trial
Characteristic | Genotyped Study Cohort N = 350 | Full E2190/INT-0121 Cohort N = 540 | P-value1 |
|---|---|---|---|
| Â | Median (IQR)2 | Median (IQR)2 | Â |
Age | 45 (39 to 50) | 44 (38 to 50) | 0.35 |
Axillary LN positive | 14 (11 to 19) | 14 (11 to 18) | 0.13 |
Tumor size, cm | 3.5 (2.1 to 5.0) | 3.5 (2.1 to 5.0) | 0.90 |
Median follow-up years | 9.8 (8.3 to 11.2) | 9.7 (8.1 to 11.4) | 0.57 |
| Â | Percent (95% CI) | Percent (95% CI) | Â |
Postmenopausal | 31 (26 to 35) | 29 (25 to 33) | 0.22 |
Race - Caucasian | 90 (87 to 93) | 89 (86 to 91) | 0.58 |
ER + | 59 (54 to 64) | 60 (56 to 64) | 0.70 |
PR + | 56 (51 to 61) | 59 (54 to 63) | 0.12 |
Lumpectomy | 17 (13 to 20) | 19 (15 to 22) | 0.10 |
Treatment arm CAF+HDC | 57 (51 to 62) | 50 (47 to 54) | <0.001 |
10-year DFS (%) | 39 (34 to 44) | 43 (38 to 47) | 0.02 |
10-year OS (%) | 45 (40 to 51) | 48 (44 to 52) | 0.09 |